VIENNA – On track to file for regulatory approval later this year in both the U.S. and Europe, Intercept Pharmaceuticals Inc. solidified its position as a research leader in the nonalcoholic steatohepatitis (NASH) with liver fibrosis field, presenting a broader dataset of its phase III trial of obeticholic acid (OCA, Ocaliva).